Semaglutide vs. Tirzepatide in Port Saint Lucie: Which GLP-1 Is Right for You?

GLP-1 medications have changed how we think about medical weight loss. Patients who have struggled for years with traditional diets are now seeing real, sustainable results - often within months. But when you sit down for your first consultation, two medications come up almost every time: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound). They are not the same drug, they do not work the same way, and the right choice depends on more than just the number on the prescription pad.

At AVAANDI MedSpa in Port Saint Lucie, our clinical team guides patients through this decision every day. This guide walks through how each medication works, what the head-to-head clinical data shows, what side effects to expect, and how to think about cost - so that when you book your medical weight loss consultation, you walk in with the background you need to make an informed decision with your provider.

How semaglutide and tirzepatide actually work

Both medications are injectable, once-weekly prescriptions that mimic hormones your body already produces to regulate hunger, fullness, and blood sugar. The difference is in which hormones they mimic.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is released by the intestine after you eat. It tells your pancreas to release insulin, tells your stomach to empty more slowly, and tells your brain you are full. Semaglutide mimics GLP-1 and does all three.

Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is a second gut hormone that works alongside GLP-1 to regulate metabolism and appetite. By hitting both receptors, tirzepatide produces a stronger appetite-suppressing and metabolic effect in most patients.

Think of it this way: semaglutide uses one mechanism, tirzepatide uses two. That difference in mechanism shows up in the weight-loss numbers.

What the clinical trials show

The two medications have been studied head-to-head and the results are consistent with what the mechanism predicts.

In the STEP 1 trial published in the New England Journal of Medicine in 2021, patients taking semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo (Wilding JPH et al., NEJM 2021). In the SURMOUNT-1 trial published in NEJM in 2022, patients taking tirzepatide 15 mg weekly lost an average of 22.5% of body weight over 72 weeks (Jastreboff AM et al., NEJM 2022).

A direct head-to-head trial (SURMOUNT-5, published in 2025) confirmed what the separate trials suggested: patients on tirzepatide lost meaningfully more weight than patients on semaglutide over the same treatment window.

This does not mean tirzepatide is automatically the right answer. It means that on average, the maximum weight-loss potential of tirzepatide is higher. Individual results depend on dose tolerance, side-effect profile, comorbidities, and adherence.

Side effects and what to actually expect

Both medications share the same general side-effect profile, and it is worth knowing what is common, what is bothersome, and what is rare-but-serious.

Most patients experience some gastrointestinal side effects in the first 4-8 weeks as the dose escalates. These typically include:

• Nausea (the most common - present in roughly 30-40% of patients at some point during titration)
• Constipation or diarrhea
• Reduced appetite and early satiety (this is the therapeutic effect, not a side effect, but it takes getting used to)
• Fatigue and occasional headaches
• Reflux or heartburn

Most side effects are manageable with slow dose escalation, hydration, and simple dietary adjustments (smaller meals, lower-fat food during titration). Tirzepatide users sometimes report a slightly higher incidence of GI symptoms than semaglutide users, consistent with its stronger pharmacologic effect.

Rare but serious side effects - documented on the label for both medications - include pancreatitis, gallbladder disease, and kidney injury. Both medications carry a boxed warning about thyroid C-cell tumors (seen in rodent studies); they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your provider will screen for these before prescribing.

A note on patients with underlying hormonal issues. Weight gain is not always a calorie problem. If your weight gain coincided with perimenopause, post-partum, thyroid changes, or sustained high stress, a GLP-1 alone may underperform. Our team often recommends pairing medical weight loss with hormone replacement therapy when the underlying driver is hormonal - addressing both levers produces better results than either alone.

Cost, access, and compounded options

Brand-name Wegovy and Zepbound can cost more than $1,000 per month without insurance coverage, and coverage for weight-loss indications remains inconsistent across plans. For many patients this is the deciding factor.

The FDA has permitted compounding pharmacies to produce semaglutide and tirzepatide in specific circumstances, which has meaningfully expanded access (FDA Zepbound approval, Nov 2023). Pricing for physician-supervised compounded GLP-1 programs typically falls in the $299-$399 per month range, all-inclusive - substantially below branded retail pricing. AVAANDI's medical weight loss program uses pharmaceutical-grade compounded options when brand coverage is not available; current all-in pricing is published on our pricing page.

Not every patient is a candidate for compounded GLP-1s. The decision depends on medical history, insurance coverage, dose requirements, and regulatory status at the time of prescribing. Your first consultation includes a full review so you know which option is realistic for you.

How we choose between them in the clinic

There is no single "better" GLP-1. The right choice depends on the specific patient in front of us.

We tend to consider tirzepatide when:

• A patient's weight-loss goal is substantial (more than 15% of body weight) and timeline matters
• The patient has well-controlled nausea tolerance and no history of significant GI conditions
• Previous trials of semaglutide produced plateau or insufficient response

We tend to consider semaglutide when:

• A patient is starting GLP-1 therapy for the first time and we want a more gradual titration
• The patient has tried and tolerated semaglutide previously
• Cost or supply of tirzepatide is a meaningful barrier
• The patient has specific side-effect sensitivities that make the lower-intensity option preferable

Every decision is individualized. We do not start at the strongest dose. We do not chase the biggest number. We match the medication, the dose, and the titration schedule to what your body actually tolerates - and we adjust based on how you respond over the first 90 days.

What your first consultation looks like

A first consultation at AVAANDI for medical weight loss is not a sales pitch. It is a clinical workup. Expect:

• A full medical history review, including prior weight-loss attempts, medications, and comorbidities
• A metabolic and thyroid panel (we cannot safely prescribe GLP-1s without this)
• A conversation about goals, timeline, and what changes you are willing to make alongside medication
• A transparent discussion of semaglutide vs. tirzepatide based on your specific profile
• A written treatment plan with dose, titration schedule, monthly check-in cadence, and clear criteria for adjusting or stopping

If medication is appropriate, we start at the lowest effective dose and titrate based on tolerance - not on a fixed schedule. If medication is not appropriate, we say so and discuss alternatives.

Frequently Asked Questions

Is tirzepatide better than semaglutide?

Tirzepatide has shown higher average weight loss than semaglutide in both separate and head-to-head clinical trials. However, "better" depends on the individual. Patients with lower weight-loss goals, slower titration needs, specific side-effect sensitivities, or cost constraints may do better on semaglutide. A clinical consultation is the only way to determine which is appropriate for you.

How fast will I lose weight on semaglutide or tirzepatide?

Most patients see meaningful weight loss within 8-12 weeks of starting treatment, with the most pronounced results between months 3 and 12. In the STEP 1 trial, significant weight loss was observed by week 20. Results depend on dose, adherence, diet, and activity - the medication is not a substitute for these, it is a tool that makes them work better.

Are compounded semaglutide and tirzepatide safe?

Compounded versions can be safe when produced by a licensed compounding pharmacy under physician supervision, using pharmaceutical-grade active ingredients. Safety depends on the source, the provider, and appropriate medical oversight. At AVAANDI, all compounded GLP-1 prescriptions go through full clinical workup and monthly follow-up, the same as brand-name options.

What are the side effects of GLP-1 medications?

The most common side effects are gastrointestinal - nausea, constipation, diarrhea, reduced appetite - especially during the first 4-8 weeks as the dose escalates. Most are manageable with slow titration and dietary adjustments. Rare but serious side effects include pancreatitis, gallbladder disease, and kidney injury; both medications carry a boxed warning regarding thyroid C-cell tumors. A thorough medical history is required before starting either.

How much do semaglutide and tirzepatide cost in Port Saint Lucie?

Branded Wegovy and Zepbound can exceed $1,000 per month without insurance coverage. Compounded options at physician-supervised programs like AVAANDI's typically range $299-$399 per month all-inclusive, depending on dose and treatment tier. Current pricing and packages are published on our pricing page.

Ready to talk about medical weight loss?

If you are weighing semaglutide against tirzepatide - or trying to figure out whether a GLP-1 is the right approach at all - the next step is a clinical consultation with a provider who can look at your specific history and build a plan around it. Book a medical weight loss consultation at AVAANDI MedSpa in Port Saint Lucie, or call (772) 742-2111.

Medical disclaimer: This article is for educational purposes and does not constitute medical advice. GLP-1 medications are prescription drugs with real contraindications and risks. Consult a qualified physician before starting, changing, or stopping any medication. Individual results vary.

References:

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. (STEP 1 trial)
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. (SURMOUNT-1 trial)
3. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound). November 8, 2023.